The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Cisplatin and Etoposide as First-line Chemotherapy for Poorly Differentiated Neuroendocrine Carcinoma of the Hepatobiliary Tract and Pancreas
Abstract
OBJECTIVE: The combination chemotherapy consisting of cisplatin and etoposide, one of the standard regimens for small cell lung cancer, has been widely used to treat extrapulmonary poorly differentiated neuroendocrine carcinomas. However, there were no prior reports limited to the hepatobiliary tract and pancreas as the primary sites. METHODS: We reviewed the cases in our database from October 1995 to January 2009 and retrospectively examined the clinical data of patients, with unresectable or recurrent poorly differentiated neuroendocrine carcinoma arising from the hepatobiliary tract and pancreas, who received combination chemotherapy with cisplatin and etoposide as the first-line treatment. The chemotherapy regimen consisted of cisplatin 80 mg/m(2) given intravenously on day 1 and etoposide 100 mg/m(2) intravenously on days 1-3, repeated every 3-4 weeks. RESULTS: Twenty-one patients were treated with the above regimen of cisplatin and etoposide combination chemotherapy. The primary tumor site was the liver in 2 patients, gallbladder in 8 patients, pancreas in 10 patients and ampulla of Vater in 1 patient. Although no complete responses were obtained, three patients had partial responses, resulting in an overall response rate of 14%. Median progression-free survival was 1.8 months, and median overall survival was 5.8 months. The major adverse events were myelosuppression and gastrointestinal toxicities, with Grade 3 or 4 neutropenia (90%), nausea (33%) and anorexia (24%). CONCLUSIONS: Cisplatin and etoposide combination as the first-line chemotherapy for hepatobiliary or pancreatic poorly differentiated neuroendocrine carcinoma had only marginal antitumor activity and relatively severe toxicity compared with previous studies on extrapulmonary poorly differentiated neuroendocrine carcinoma treated with the same regimen.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
on Behalf of the Japan Clinical Oncology Group (JCOG)-Lung Cancer Study Group, Okamoto, H., Watanabe, K., Kunikane, H., Yokoyama, A., Kudoh, S., Asakawa, T., Shibata, T., Kunitoh, H., Tamura, T., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603810 · Cited by 213
Cited by
Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Shah, M. H., Goldner, W. S., Benson, A. B., Bergsland, E., Blaszkowsky, L. S., Brock, P., Chan, J., Das, S., Dickson, P. V., Fanta, P., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0032 · Cited by 619
Garcia-Carbonero, R., Sorbye, H., Baudin, E., Raymond, E., Wiedenmann, B., Niederle, B., Sedlackova, E., Toumpanakis, C., Anlauf, M., Cwikla, J. B., et al. (2016) · Neuroendocrinology · doi:10.1159/000443172 · Cited by 611
Yachida, S., Vakiani, E., White, C. M., Zhong, Y., Saunders, T., Morgan, R., de Wilde, R. F., Maitra, A., Hicks, J., DeMarzo, A. M., et al. (2012) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3182417d36 · Cited by 534
Welin, S., Sorbye, H., Sebjornsen, S., Knappskog, S., Busch, C., & Öberg, K. (2011) · Cancer · doi:10.1002/cncr.26124 · Cited by 288
Basturk, O., Tang, L., Hruban, R. H., Adsay, V., Yang, Z., Krasinskas, A. M., Vakiani, E., La Rosa, S., Jang, K.-T., Frankel, W. L., et al. (2014) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000169 · Cited by 258
Metadata
- Authors
- Iwasa, S., Morizane, C., Okusaka, T., Ueno, H., Ikeda, M., Kondo, S., Tanaka, T., Nakachi, K., Mitsunaga, S., Kojima, Y., Hagihara, A., & Hiraoka, N.
- Venue
- Japanese Journal of Clinical Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-01-04
- Volume
- 40
- Issue
- 4
- Pages
- 313-318
- ISSN
- 0368-2811 (ISSN-L)
- 1465-3621
- OpenAlex
- W2123965872
- Cited by
- 170
- References
- 1
- FWCI
- 4.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cisplatin and Etoposide as First-line Chemotherapy for Poorly Differentiated Neuroendocrine Carcinoma of the Hepatobiliary Tract and Pancreas. https://app.cochat.ai/papers/10.1093/jjco/hyp173
- The paper
- Iwasa, S., Morizane, C., Okusaka, T., Ueno, H., Ikeda, M., Kondo, S., Tanaka, T., Nakachi, K., Mitsunaga, S., Kojima, Y., Hagihara, A., & Hiraoka, N. (2010). Cisplatin and Etoposide as First-line Chemotherapy for Poorly Differentiated Neuroendocrine Carcinoma of the Hepatobiliary Tract and Pancreas. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyp173
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.